# Doravirine, Rifapentine and Isoniazid Interaction

> **NCT03886701** · PHASE1 · COMPLETED · sponsor: **Walter K. Kraft** · enrollment: 11 (actual)

## Conditions studied

- Latent Tuberculosis
- Human Immunodeficiency Virus
- Rifamycins Causing Adverse Effects in Therapeutic Use
- Drug Interaction Potentiation

## Interventions

- **DRUG:** Doravirine (DOR)
- **DRUG:** Rifapentine (RPT)
- **DRUG:** Isoniazid (INH)

## Key facts

- **NCT ID:** NCT03886701
- **Lead sponsor:** Walter K. Kraft
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-22
- **Primary completion:** 2019-05-20
- **Final completion:** 2019-05-20
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03886701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03886701, "Doravirine, Rifapentine and Isoniazid Interaction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03886701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*